{"text": "Results showed a minimal change in the in - scaffold late lumen loss ( LLL ) between 6 and 18 months ( 0.25 to 0.31 mm mean LLL ; median 0.13 to 0.21 mm LLL ; with a mean and median change of 0.07 mm and 0.04 mm , respectively ) .", "label": "", "metadata": {}, "score": "35.744877"}
{"text": "Clinical follow - up for up to 5 years will be conducted by telephone .The primary endpoint is in - segment late lumen loss at 9 months measured by quantitative coronary angiography .", "label": "", "metadata": {}, "score": "36.23949"}
{"text": "Clinical follow - up for up to 5 years will be conducted by telephone .The primary endpoint is in - segment late lumen loss at 9 months measured by quantitative coronary angiography .", "label": "", "metadata": {}, "score": "36.23949"}
{"text": "The primary endpoint was the late lumen loss after 6 months follow - up as seen in angiography .Secondary endpoints included the rate of restenosis ( a binary variable ) , change of ankle brachial index ( ABI ) , rutherford class and major adverse events .", "label": "", "metadata": {}, "score": "48.60079"}
{"text": "We hypothesize that the IA - DEB will significantly reduce angiographically assessed target lesion late lumen loss ( LLL ) compared to standard PTA in infrapopliteal lesions up to 10 cm in length and reduce clinically driven target lesion revascularization ( TLR ) in amputation - free surviving CLI patients through 12 months .", "label": "", "metadata": {}, "score": "57.29258"}
{"text": "[ Time Frame : 12 months ] [ Designated as safety issue : No ] .In - segment late loss measured by quantitative angiography .", "label": "", "metadata": {}, "score": "62.858276"}
{"text": "In - stent late loss measured by quantitative angiography .[ Time Frame : 12 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "64.49121"}
{"text": "In - segment late loss measured by quantitative angiography .[ Time Frame : 12 months ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "67.645035"}
{"text": "A QoL questionnaire including a pain scale will assess changes from baseline scores through 12 months .A Clinical Events Committee and Data Safety Monitoring Board will adjudicate the composite primary safety endpoints of all - cause death , major amputation , and clinically driven TLR at 6 months and other trial endpoints and supervise patient safety throughout the study .", "label": "", "metadata": {}, "score": "67.939804"}
{"text": "In prospective clinical trials in relatively small CLI patient cohorts , tibial vessel drug - eluting balloon ( DEB ) angioplasty was associated with significantly reduced restenosis rates and late lumen loss ( LLL ) at 3 , 6 , and 12 months [ 17 - 19 ] .", "label": "", "metadata": {}, "score": "69.05577"}
{"text": "The trial will determine the efficacy and safety of the novel Yukon Choice stent system compared to the well established Taxus Libert\u00e9 stent system .The primary endpoint will be \" in - stent late lumen loss \" at 9 months as determined by invasive angiography .", "label": "", "metadata": {}, "score": "69.55992"}
{"text": "CK creatine kinase , ECG electrocardiogram .Study endpoints .The primary endpoint is LLL at 9 months as assessed by quantitative coronary angiography .The secondary endpoints are divided in angiographic and clinical findings .", "label": "", "metadata": {}, "score": "70.083206"}
{"text": "LLL assessment is considered the most sensitive , objective determinant of post - intervention vessel narrowing ; this methodology was accordingly selected as the best arbiter of a potential DEB treatment effect .", "label": "", "metadata": {}, "score": "70.996155"}
{"text": "Original Secondary Outcome Measures ICMJE ( submitted : March 18 , 2008 ) .Mean percent diameter stenosis ( % DS ) and minimal lumen diameter ( MLD ) measured by quantitative angiography post - procedure .", "label": "", "metadata": {}, "score": "71.00519"}
{"text": "Safety and quality control .Data safety monitoring board .A Clinical Events Committee ( CEC ) will assess the composite primary safety endpoints of all - cause death , major amputation , and clinically driven TLR through 12 months and will adjudicate other trial endpoints .", "label": "", "metadata": {}, "score": "71.07116"}
{"text": "TLR risk was maximal between 3 to 6 years .New lesion revascularization increased throughout the study period .Conclusion Incidence of TLR was maximal 3 to 6 years after SES implantation and decreased thereafter .", "label": "", "metadata": {}, "score": "71.15228"}
{"text": "Conclusions : This study suggests that PFO closure with APFO or CPFO is equally effective for the prevention of recurrent events .Residual shunt was more frequent at six months with CPFO , but was similar to APFO at later follow - up .", "label": "", "metadata": {}, "score": "71.29523"}
{"text": "Mean luminal diameter of the stent , peristent segments , and of a control vessel were determined at rest , during exercise , and after the administration of nitroglycerine .", "label": "", "metadata": {}, "score": "71.36699"}
{"text": "Assessment for stent fractures by X - Ray .[ Time Frame : 12 months ] [ Designated as safety issue : No ] .[ Time Frame : post procedure ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "71.65556"}
{"text": "However , intervention in TASC A and B lesions ( max .15 cm ) to restore adequate blood flow , in the same index procedure is allowed .", "label": "", "metadata": {}, "score": "72.00804"}
{"text": "The hypothesized treatment effect - that is , the mean difference between the IA - DEB and PTA arms at 12 months .An estimate of variability , specifically the standard deviation ( SD ) .", "label": "", "metadata": {}, "score": "72.05295"}
{"text": "The pre - specified endpoint at three years was major adverse cardiac events ( MACE ) , a composite of cardiac death , non - fatal myocardial infarction ( MI ) , or target vessel revascularisation ( TVR ) .", "label": "", "metadata": {}, "score": "72.22513"}
{"text": "Two large clinical trials ( NOBORI and LEADERS ) proved its non - inferiority to PES and SES at 9 months and 4 years , respectively [ 9 , 10 ] .", "label": "", "metadata": {}, "score": "72.36211"}
{"text": "At screening , 6 weeks , 6 and 12 months ] [ Designated as safety issue : No ] .Ankle Brachial Index measured [ Time Frame :", "label": "", "metadata": {}, "score": "72.66369"}
{"text": "This multicenter trial has enrolled 358 patients at 13 European centers with independent angiographic core lab adjudication of the primary efficacy endpoint of target lesion late luminal loss ( LLL ) and clinically driven target lesion revascularization ( TLR ) in major amputation - free surviving patients through 12-months .", "label": "", "metadata": {}, "score": "72.73679"}
{"text": "In - stent late lumen loss , which represents the amount of tissue growth within a stent , reduces the diameter of the lumen , thus restricting blood flow through the stent .", "label": "", "metadata": {}, "score": "72.8331"}
{"text": "[ Time Frame : 6 weeks , 6 and 12 months ] [ Designated as safety issue : No ] .Target Lesion Revascularization ( TLR ) , and Target Vessel Revascularization ( TVR ) .", "label": "", "metadata": {}, "score": "73.16972"}
{"text": "A second - generation device was developed to overcome the initial limitations of early scaffold shrinkage and provide greater radial support .Putative advantages over conventional DES are early restoration of physiological processes , namely vasomotion and remodeling , superior conformability , beneficial edge - vascular response and suppression of late - stent malapposition [ 27 ] .", "label": "", "metadata": {}, "score": "73.38466"}
{"text": "[ Time Frame : 6 weeks , 6 and 12 months ; ] [ Designated as safety issue : No ] .Ankle Brachial Index measured at screening .", "label": "", "metadata": {}, "score": "73.588554"}
{"text": "Randomization of subjects proceeded after all procedural and angiographic eligibility criteria had been met , including the requirements that all inflow lesions had been successfully treated and that the guidewire had successfully crossed the target lesion and was positioned into the distal true lumen ( Table 1 ) .", "label": "", "metadata": {}, "score": "73.755905"}
{"text": "All patients will be monitored between 4 to 12 h in an intermediate care unit and will undergo baseline and 3 to 6 h cardiac biomarker measurements .", "label": "", "metadata": {}, "score": "74.06859"}
{"text": "The primary endpoint was a composite of death , myocardial infarction ( MI ) and target vessel revascularisation ( TVR ) at two - year follow - up .", "label": "", "metadata": {}, "score": "75.446014"}
{"text": "This is primarily due to a hypersensitivity reaction with secondary delayed arterial healing [ 24 , 25 ] .Substantial efforts have been made during the last decade to develop bioresorbable materials such as transient polymers or temporary ' scaffolds ' .", "label": "", "metadata": {}, "score": "75.98598"}
{"text": "The primary co - efficacy endpoint of 12-month TLR is powered to 65 % with the indicated sample size .Primary co - efficacy endpoints .", "label": "", "metadata": {}, "score": "76.81874"}
{"text": "As this is an ITT analysis , subjects receiving provisional stents will be tracked in their respective assigned randomized trial arms .A completion digital subtraction angiogram in two oblique views of the TL and pedal run - off was required .", "label": "", "metadata": {}, "score": "77.09138"}
{"text": "Excised mouse aortas containing atherosclerotic plaque were ablated with ultrafast near - infrared ( NIR ) laser pulses .Optical coherence tomography ( OCT ) was used to observe the ablation result , while the physical damage was inspected in histological sections .", "label": "", "metadata": {}, "score": "77.54814"}
{"text": "Detailed Description .This is a multicenter , prospective , randomized study to be conducted in 18 centers in Europe .All subjects will undergo a repeat angiography at 12 months to assess the primary endpoint of In - Segment Binary Restenosis .", "label": "", "metadata": {}, "score": "77.63657"}
{"text": "Patients will be followed clinically by clinic visits or by telephone interview at 3 , 6 , 9 and 12 months , and 2 and 5 years .", "label": "", "metadata": {}, "score": "77.63669"}
{"text": "This interim look would permit early stopping for efficacy using an O'Brien - Fleming - type alpha - spending function .Based on 150 out of 357 total enrolled subjects in the trial , the two - sided P -values required at the interim and final looks will be 0.006 and 0.048 , respectively .", "label": "", "metadata": {}, "score": "77.65155"}
{"text": "Patients received clinical follow - up at 30 days and six months and will be followed annually through five years .Primary endpoint data from the NEVO RES I trial were presented at the EuroPCR meeting in May of this year .", "label": "", "metadata": {}, "score": "77.88101"}
{"text": "One propensity score matched registry ( LESSON-1 ) showed a trend towards a lower risk of death , myocardial infarction ( MI ) and target - vessel revascularization ( TVR ) as compared to SES over a 3-year follow - up [ 8 ] .", "label": "", "metadata": {}, "score": "77.97107"}
{"text": "All subjects from both cohorts will be part of the clinical assessment and followed for 5 years post - randomization .Only subjects from the Angio cohort will undergo angiographic evaluation at 12 months .", "label": "", "metadata": {}, "score": "78.61537"}
{"text": "Background .The effectiveness and durability of endovascular revascularization therapies for chronic critical limb ischemia ( CLI ) are challenged by the extensive burden of infrapopliteal arterial disease and lesion - related characteristics ( e.g. , severe calcification , chronic total occlusions ) , which frequently result in poor clinical outcomes .", "label": "", "metadata": {}, "score": "78.74094"}
{"text": "Secondary sustained clinical improvement : an improvement shift in the Rutherford classification of 1 class including the need for clinically driven TLR in amputation - free surviving patients at 1 year .", "label": "", "metadata": {}, "score": "79.01412"}
{"text": "Follow - up coronary angiography .Effectiveness will be measured at the 9-month follow - up angiography in all patients .Quantitative measures will be performed within the stent and the 5 mm edge region .", "label": "", "metadata": {}, "score": "79.33157"}
{"text": "These results help us to understand the two different approaches more clearly .\" Nine - month clinical outcomes from the REMEDEE study were previously presented at TCT 2011", "label": "", "metadata": {}, "score": "79.69963"}
{"text": "It will assess the overall impact on infrapopliteal artery patency , limb salvage , wound healing , pain control , QoL , and patient mobility .", "label": "", "metadata": {}, "score": "79.77753"}
{"text": "Methods / Design .Trial design .This trial is a 2:1 randomized , controlled , patient - blinded multicenter trial that compares the IA - DEB to PTA in terms of angiographically assessed target lesion LLL and clinically driven TLR of infrapopliteal arteries in Rutherford class 4 - 5 - 6 symptomatic critical limb ischemia patients through 12 months ( Figure 1 ) .", "label": "", "metadata": {}, "score": "79.87889"}
{"text": "3 Within 6 weeks of procedure .4 For Angio Sub - group subjects only .5 If subject undergoes an unscheduled angiogram ; a copy of the angiogram must be forwarded to the Angiographic Core Lab for adjudication .", "label": "", "metadata": {}, "score": "80.012886"}
{"text": "i.6 Reference vessel diameter(s ) between 2 and 4 mm . i.8 At least one non - occluded crural vessel with angiographically documented run - off to the foot either directly or through collaterals .", "label": "", "metadata": {}, "score": "80.30257"}
{"text": "Blevins WA Jr , Schneider PA : Endovascular management of critical limb ischemia .Eur J Vasc Endovasc Surg 2010 , 39 ( 6):756 - 761 .", "label": "", "metadata": {}, "score": "80.51914"}
{"text": "Target Lesion Revascularization ( TLR ) , and Target Vessel Revascularization ( TVR ) .[ Time Frame : 6 weeks , 6 and 12 months ; ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "80.53366"}
{"text": "Recent data suggest that patients who experienced tibial PTA restenosis and who subsequently underwent a lower limb bypass required more distal target anastomoses [ 15 ] and had higher 1-year amputation and graft closure rates [ 16 ] when compared to patients without prior PTA .", "label": "", "metadata": {}, "score": "80.57687"}
{"text": "PubMed View Article .S\u00f6derstr\u00f6m M , Arvela E , Venermo M , Lep\u00e4ntalo M , Alb\u00e4ck A : Tertiary patency as a measure of active revascularization policy for leg salvage .", "label": "", "metadata": {}, "score": "80.66628"}
{"text": "b Secondary endpoints : patient oriented ( death , myocardial infarction , target vessel revascularization ) , device oriented ( cardiac death , myocardial infarction , target - lesion revascularization ) , stent thrombosis , binary restenosis at 9-month angiography study .", "label": "", "metadata": {}, "score": "81.02618"}
{"text": "164 .PubMed View Article .Kudo T , Chandra FA , Ahn SS : The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia : a 10-year experience .", "label": "", "metadata": {}, "score": "81.02969"}
{"text": "Therefore , there is an evolving concern that CLI patients followed for a longer time period will demonstrate high tibial PTA restenosis rates that may ultimately require lower extremity bypass , which are , in turn , associated with higher bypass failure rates and worse outcomes [ 16 ] .", "label": "", "metadata": {}, "score": "81.055046"}
{"text": "PubMed View Article .Haider SN , Kavanagh EG , Forlee M , Colgan MP , Madhavan P , Moore DJ , Shanik GD : Two - year outcome with preferential use of infrainguinal angioplasty for critical ischemia .", "label": "", "metadata": {}, "score": "81.19118"}
{"text": "Methods and results : The primary endpoint was a composite of stroke , TIA , or peripheral embolism at follow - up .The secondary endpoint was residual shunt .", "label": "", "metadata": {}, "score": "81.21817"}
{"text": "Secondary endpoints included patient - oriented major acute coronary events ( MACE ) ( death , myocardial infarction [ MI ] , and any revascularization ) , device - oriented MACE ( cardiac death , MI , and target lesion revascularization ) , and stent thrombosis at the 9-month clinical follow - up .", "label": "", "metadata": {}, "score": "81.25212"}
{"text": "Iida [ 25 ] and Neville [ 27 ] demonstrated significantly improved wound healing and rates of freedom from amputation when direct pulsatile flow via the WRA was established compared to when indirect revascularization was implemented .", "label": "", "metadata": {}, "score": "81.53492"}
{"text": "PubMed View Article .Manzi M , Cester G , Palena LM , Alek J , Candeo A , Ferraresi R : Vascular imaging of the foot : the first step toward endovascular recanalization .", "label": "", "metadata": {}, "score": "81.570145"}
{"text": "Amputation .[ Time Frame : 6 weeks , 6 and 12 months ] [ Designated as safety issue : No ] .Quality of Life assessment .", "label": "", "metadata": {}, "score": "81.60913"}
{"text": "Nonetheless , reports that include adjudication of restenosis rates by an independent angiographic core lab as part of a large multicenter randomized controlled trial are lacking .", "label": "", "metadata": {}, "score": "82.32608"}
{"text": "Three - Year Results from the EXCELLA BD Randomized Clinical Trial for the CE Mark - Approved DESyne BD System with Biodegradable Polymer Coating Continues Reporting No Stent Thrombosis .", "label": "", "metadata": {}, "score": "82.352234"}
{"text": "In addition , the plaque may rupture , due to the atherosclerotic burden , leading to vessel occlusion , blood flow interruption , and acute coronary syndrome .", "label": "", "metadata": {}, "score": "82.760635"}
{"text": "An independent Wound Core Lab .( SynvaCor , Springfield , IL ) subsequently adjudicated data .USA .Important \" patient - centric \" secondary endpoints to be assessed include time to wound healing , change in ischemic pain , quality of life ( QoL ) , and walking capacity .", "label": "", "metadata": {}, "score": "83.13384"}
{"text": "LLL is computed through quantitative coronary angiography with the use of automated edge - detection system ( CAAS II , Pie Medical Imaging , Maastricht , The Netherlands ) .", "label": "", "metadata": {}, "score": "83.42149"}
{"text": "[ Time Frame : 12 months ] [ Designated as safety issue : No ] .Patency defined as detectable flow measured by Duplex Ultrasound .", "label": "", "metadata": {}, "score": "83.457565"}
{"text": "Serious Adverse Events at procedure up to discharge .[ Time Frame : 6 weeks , 6 and 12 months ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "83.81499"}
{"text": "Early trial termination .An interim analysis of 150 subjects at 12 months to assess the primary safety and efficacy endpoints is to be performed by an independent group and maintained confidentially .", "label": "", "metadata": {}, "score": "83.90091"}
{"text": "Procedural success defined as combination of technical success , device success and absence of procedural complications .For the Angio cohort : improvement in 12 months of percent diameter stenosis ( % DS ) of the TL assessed by quantitative vascular angiography .", "label": "", "metadata": {}, "score": "83.96521"}
{"text": "Yet , despite concerns of high infrapopliteal PTA restenosis rates , the limb salvage rates appear acceptable [ 10 ] when compared to open lower limb bypass [ 12 ] .", "label": "", "metadata": {}, "score": "84.13873"}
{"text": "Ideally , the device would offer an acute transient radial strength and later be completely absorbed thereby restoring vascular physiology .Several DES using bioresorbable materials are currently available .", "label": "", "metadata": {}, "score": "84.453156"}
{"text": "This trial is expected to enroll approximately 1,900 patients .The NIREUS trial aims to demonstrate angiographic non - inferiority of the NIRsupreme stent to a comparator stent and has a primary endpoint of late loss in lumen diameter within the stent determined by coronary angiography at six months .", "label": "", "metadata": {}, "score": "84.8706"}
{"text": "Additional analyses from the REMEDEE trial for OrbusNeich 's Combo Dual Therapy Stent were also featured at the congress .For the study in STEMI patients , the primary endpoint was the rate of major adverse cardiac events ( MACE ) , defined as death , myocardial infarction ( MI ) , target vessel revascularization ( TVR ) and ST , between one and three years .", "label": "", "metadata": {}, "score": "84.87315"}
{"text": "Over time , fibrous atherosclerotic plaques develop , narrowing the arteries and thereby limiting coronary blood flow .At this stage , coronary artery disease can be asymptomatic or associated with angina pectoris , and it is typically accompanied by calcification of the atherosclerotic plaque .", "label": "", "metadata": {}, "score": "84.969315"}
{"text": "TZ , IB , DS , and ML conceived and participated in the design of the study .MBR , MBO , AM , PP , and FV contributed to the design of the study .", "label": "", "metadata": {}, "score": "85.0049"}
{"text": "Serious Adverse Events [ Time Frame : At procedure up to discharge , 6 weeks , 6 and 12 months ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "85.53281"}
{"text": "Amputation [ Time Frame : 6 weeks , 6 and 12 months ] [ Designated as safety issue : Yes ] .Quality of Life assessment .", "label": "", "metadata": {}, "score": "85.613174"}
{"text": "Lesions located at the bifurcation requiring treatment of both branches ( 1 in main branch and 1 in side branch ) ; .Required stent placement across or within 1 cm of the knee joint ; in an artery subject to external compression , or in an artery directly subject to movement of the ankle or knee joint ; .", "label": "", "metadata": {}, "score": "85.718994"}
{"text": "All patients were required to be free of further general procedural exclusion criteria ( Table 1 Section E ) such as unsuccessful crossing of the target lesion with a guide wire .", "label": "", "metadata": {}, "score": "85.92651"}
{"text": "PubMed .Lancet 2013 , 381 : 651 - 660 .10.1016/S0140 - 6736(12)61852 - 2 View Article PubMed .Jukema JW , Ahmed TA , Verschuren JJ , Quax PH : Restenosis after PCI .", "label": "", "metadata": {}, "score": "86.16394"}
{"text": "Department of Cardiology , University & Hospital .References .Dibra A , Kastrati A , Alfonso F , Seyfarth M , P\u00e9rez - Vizcayno MJ , Mehilli J , Sch\u00f6mig A : Effectiveness of drug - eluting stents in patients with bare - metal in - stent restenosis : meta - analysis of randomized trials .", "label": "", "metadata": {}, "score": "86.25464"}
{"text": "Outcomes and follow - up were obtained in all 200 patients .The cumulative 10-year MACE rate was 47 % with all - cause death of 20 % , cardiac death of 9 % , myocardial infarction of 7 % , TLR and TVR of 8 % and 11 % respectively .", "label": "", "metadata": {}, "score": "87.024994"}
{"text": "PubMed View Article .Circulation 2013 .[ Epub ahead of print ] .Tepe G , Zeller T , Albrecht T , Heller S , Schwarzw\u00e4lder U , Beregi JP , Claussen CD , Oldenburg A , Scheller B , Speck U : Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg .", "label": "", "metadata": {}, "score": "87.081566"}
{"text": "Complex cardiac procedures were associated with higher heart rates up to 122 bpm .Peak heart rates were higher during physical exertion .Some subjects complained of hypersexuality and mania after night shifts .", "label": "", "metadata": {}, "score": "87.14294"}
{"text": "To permit early stopping of the trial for overwhelming efficacy ( and not futility ) .For use in designing and powering a subsequent United Stated Investigational Device Exemption ( US IDE ) trial .", "label": "", "metadata": {}, "score": "87.32855"}
{"text": "All patients will receive either a minimum 600 mg loading dose of clopidogrel , 180 mg of ticagrelor , or 60 mg prasugrel before or immediately after the procedure .", "label": "", "metadata": {}, "score": "87.39348"}
{"text": "PubMed View Article .Nolan BW , De Martino RR , Stone DH , Schanzer A , Goodney PP , Walsh DW , Cronenwett JL , Vascular Study Group of New England : Prior failed ipsilateral percutaneous endovascular intervention in patients with critical limb ischemia predicts poor outcome after lower extremity bypass .", "label": "", "metadata": {}, "score": "87.455"}
{"text": "Utsunomiya M , Nakamura M , Nakanishi M , Takagi T , Hara H , Onishi K , Yamada T , Sugi K : Impact of wound blush as an angiographic end point of endovascular therapy for patients with critical limb ischemia .", "label": "", "metadata": {}, "score": "87.82843"}
{"text": "If the subject met the pre - specified angiographic cohort eligibility criteria ( Table 1 ) , the subject was selectively entered into the angiographic cohort trial arm .", "label": "", "metadata": {}, "score": "87.98231"}
{"text": "The Elixir DESyne BD stent utilizes a proprietary technology to enable an ultrathin biodegradable polymer coating without the need for an underlying primer layer .The biodegradable , polylactide - based material , which enables the sustained release of Elixir 's novel m - tor inhibitor , Novolimus , to the coronary vessel wall , degrades within 6 - 9 months , leaving behind the metal stent surface achieving excellent and sustained clinical outcomes .", "label": "", "metadata": {}, "score": "88.210144"}
{"text": "Still better outcomes were achieved with revascularization of a greater number of vessels .Additionally , the importance of foot vascular anatomy [ 30 ] , pedal circulation [ 31 ] , and micro - circulation [ 32 ] to CLI outcomes has been recently emphasized .", "label": "", "metadata": {}, "score": "88.23346"}
{"text": "d. .resulted in a medical or surgical intervention to prevent permanent impairment to body structure or body function .MAEs as in Figure 2 are defined as composite rates of all - cause death , minor amputation , and major amputation .", "label": "", "metadata": {}, "score": "88.23976"}
{"text": "Three - year follow - up was available in 2,683 patients ( 99.1 % ) .At three - year follow - up , MACE as well as safety and efficacy measures including stent thrombosis were not statistically different between the biodegradable polymer - coated BES and the durable polymer - coated EES .", "label": "", "metadata": {}, "score": "88.34717"}
{"text": "\" First , we observe a tighter distribution of in - stent late lumen loss for the Combo Dual Therapy Stent versus a bimodal distribution for the TAXUS Liberte stent .", "label": "", "metadata": {}, "score": "88.42883"}
{"text": "The primary safety endpoint is described below ; secondary endpoints and major inclusion / exclusion clinical and angiographic criteria are detailed in Tables 1 and 2 , respectively .", "label": "", "metadata": {}, "score": "88.63516"}
{"text": "Primary efficacy endpoints .The IN.PACT DEEP trial was designed before there was preliminary evidence of the degree of efficacy of DEB relative to PTA in the infrapopliteal vasculature .", "label": "", "metadata": {}, "score": "88.81613"}
{"text": "PubMed View Article .Neville RF , Attinger CE , Bulan EJ , Ducic I , Thomassen M , Sidawy AN : Revascularization of a specific angiosome for limb salvage : does the target artery matter ?", "label": "", "metadata": {}, "score": "88.83842"}
{"text": "Patients also reported improvements in their overall quality of life .These data demonstrate the important benefits of drug - eluting stents in reducing chest pain in patients with coronary artery disease .", "label": "", "metadata": {}, "score": "88.89572"}
{"text": "PubMed View Article .Peregrin JH , Koznar B , Kov\u00e1c J , Lastovickov\u00e1 J , Novotn\u00fd J , Vedlich D , Skibov\u00e1 J : PTA of infrapopliteal arteries : long - term clinical follow - up and analysis of factors influencing clinical outcome .", "label": "", "metadata": {}, "score": "89.055084"}
{"text": "OCT images were acquired using the pullback and nonexclusive flushing technique and analysed offline .CONCLUSIONS : BVS has fewer uncovered struts and presents with a thicker neointimal coverage compared with EES&BES .", "label": "", "metadata": {}, "score": "89.08983"}
{"text": "Primary efficacy endpoint : clinical cohort .For the efficacy endpoint of 12-month TLR , the statistical hypothesis is tested using Fisher 's exact test of proportions of IA - DEB versus PTA , again with 5 % two - sided alpha and 80 % desired power .", "label": "", "metadata": {}, "score": "89.15629"}
{"text": "PubMed View Article .Blackwelder W : \" Proving the null hypothesis \" in clinical trials .Control Clin Trials 1982 , 3 : 345 - 353 .", "label": "", "metadata": {}, "score": "89.37252"}
{"text": "PubMed View Article .Parsons RE , Suggs WD , Lee JJ , Sanchez LA , Lyon RT , Veigh FJ : Percutaneous transluminal angioplasty for the treatment of limb threatening ischemia : do the results justify an attempt before bypass grafting ?", "label": "", "metadata": {}, "score": "89.374596"}
{"text": "Patient selection criteria .Patients must be apt and willing to provide written informed consent and participate in follow - up .Patients with a known or presumed hypersensitivity to heparin , antiplatelet drugs and hypersensitivity to contrast dye not controllable with standard premedication will be excluded .", "label": "", "metadata": {}, "score": "89.43584"}
{"text": "Lancet 2005 , 366 ( 9501):1925 - 1934 .PubMed View Article .Conrad MF , Kang J , Cambria RP , Brewster DC , Watkins MT , Kwolek CJ , LaMuraglia GM : Infrapopliteal balloon angioplasty for the treatment of chronic occlusive disease .", "label": "", "metadata": {}, "score": "89.613174"}
{"text": "Importantly , no incidence of ST was observed between one and three years .The prospective study included 384 STEMI patients treated with the Genous Stent , of which 7.2 percent had cardiogenic shock and 33.1 percent had diabetes .", "label": "", "metadata": {}, "score": "89.76982"}
{"text": "PubMed View Article .Faglia E , Clerici G , Clerissi J , Mantero M , Caminiti M , Quarantiello A , Curci V , Lupattelli T , Morabito A : When is a technically successful peripheral angioplasty effective in preventing above - the - ankle amputation in diabetic patients with critical limb ischaemia ?", "label": "", "metadata": {}, "score": "89.79372"}
{"text": "PubMed View Article .Baumann F , Willenberg T , Do DD , Keo HH , Baumgartner I , Diehm N : Endovascular revascularization of below - the - knee arteries : prospective short - term angiographic and clinical follow - up .", "label": "", "metadata": {}, "score": "89.894"}
{"text": "The standard deviation of indexed LLL was assumed to be 0.25 , which is a reasonably conservative value for a random variable of this type .", "label": "", "metadata": {}, "score": "89.965225"}
{"text": "10.1016/S0140 - 6736(04)17275 - 9 View Article PubMed .Ong ATL , McFadden EP , Regar E , de Jaegere PPT , van Domburg RT , Serruys PW : Late angiographic stent thrombosis ( LAST ) events with drug - eluting stents .", "label": "", "metadata": {}, "score": "90.0338"}
{"text": "Therefore , significant lesions in the aorto - iliac and/or femoropopliteal arterial segments were treated during the index procedure .This interventional strategy conforms to standard of practice in maximizing inflow into the infrapopliteal segment in CLI patients .", "label": "", "metadata": {}, "score": "90.67155"}
{"text": "Complex cardiac procedures were associated with higher HR up to 122 bpm .Peak HR were higher during physical exertion .Of note , participants complained of hypersexuality and mania after night shifts .", "label": "", "metadata": {}, "score": "90.68507"}
{"text": "All subjects will be evaluated yearly for 5 years .Eligibility criteria .Subjects were required to meet all general , angiographic and procedural eligibility criteria ( Table 1 A - E ; see below ) to be considered for the trial .", "label": "", "metadata": {}, "score": "90.70238"}
{"text": "Primary Completion Date .January 2011 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .Inclusion Criteria : .Female of childbearing potential must have a negative pregnancy test within 10 days prior to index procedure and utilize reliable birth control until completion of the 12-month angiographic evaluation ; .", "label": "", "metadata": {}, "score": "90.909485"}
{"text": "View Article .Romiti M , Albers M , Brochado - Neto FC , Durazzo AE , Pereira CA , De Luccia N : Meta - analysis of infrapopliteal angioplasty for chronic critical limb ischemia .", "label": "", "metadata": {}, "score": "90.93608"}
{"text": "This unique design allows drug delivery from a stent with a surface that is 75 percent bare metal upon insertion and which becomes purely bare metal following drug delivery and polymer bioresorption in approximately three months based on in vivo data .", "label": "", "metadata": {}, "score": "91.055725"}
{"text": "They also emphasize that successful CLI care goes beyond promoting durable vessel patency and is but one essential aspect of a multidisciplinary team approach , an approach that is representative of the IN.PACT DEEP trial design .", "label": "", "metadata": {}, "score": "91.10519"}
{"text": "Department of Medical Affairs , Endovascular Therapies , Medtronic Cardiovascular .References .Beard JD : Which is the best revascularization for critical limb ischemia : endovascular or open surgery ?", "label": "", "metadata": {}, "score": "91.13606"}
{"text": "a.i.2 Angio - TL is the only lesion in that vessel ( only 1 Angio - TL per patient is allowed ) .( G ) Angiographic cohort general exclusion criteria .", "label": "", "metadata": {}, "score": "91.52661"}
{"text": "e.3 Lesion and/or occlusions located in or extending to the popliteal artery or below the ankle joint space .e.6 Previously implanted stent in the TL(s ) .", "label": "", "metadata": {}, "score": "91.84148"}
{"text": "Each will be tested for superiority in a comparison of the randomized groups .Sample size consideration .Primary efficacy endpoint : angiographic cohort .The statistical hypothesis of superiority is assessed using a two - sample t -test of IA - DEB versus PTA , with 5 % two - sided alpha and 80 % desired power .", "label": "", "metadata": {}, "score": "91.9771"}
{"text": "PubMed View Article .Adam DJ , Bradbury AW : TASC II document on the management of peripheral arterial disease .Eur J Vasc Endovasc Surg 2007 , 33 ( 1):1 - 2 .", "label": "", "metadata": {}, "score": "92.0598"}
{"text": "With its widespread clinical launch in 2012 , little is known on the broader use in more complex cases or acute coronary syndromes .The use of the BVS in complex situations makes sense however , as the risk of long - term complications from conventional DES implantation is even higher ( longer lesions , chronic total occlusion , acute coronary syndromes and so on ) .", "label": "", "metadata": {}, "score": "92.21269"}
{"text": "[ 12 ] was examined for results on ( binary ) primary patency .The indicated value was 58.1 % at 12 months , meaning that 58.1 % of enrolled subjects in the studies summarized had binary primary patency ( restenosis less than 50 % ) at 12 months .", "label": "", "metadata": {}, "score": "92.41921"}
{"text": "Based upon the parameters above , the mean for the PTA group is estimated to be 0.45 .This is reasonable in that it is somewhat less than 0.5 , which would be expected to be the case since more than half of subjects had binary patency .", "label": "", "metadata": {}, "score": "92.4297"}
{"text": "10.1016/S0140 - 6736(09)60325 - 1 View Article PubMed .Euro Intervention 2010 , 5 : 932 - 938 .PubMed .Rensing BJ , Vos J , Smits PC , Foley DP , van den Brand MJ , van der Giessen WJ , de Feijter PJ , Serruys PW : Coronary restenosis elimination with a sirolimus eluting stent ; First European human experience with 6-month angiographic and intravascular ultrasonic follow - up .", "label": "", "metadata": {}, "score": "92.43317"}
{"text": "Clinical follow - up will proceed as noted in Table 4 .All subjects will be followed for 5 years .2 Following the PTA procedure , subjects were to be prescribed daily acetyl - salicylic acid ( ASA ) ( 100 mg ) indefinitely and daily clopidogrel ( 75 mg ) ( or ticlopidine , if required ) for at least 1 month following the procedure .", "label": "", "metadata": {}, "score": "92.86599"}
{"text": "It uses a poly- l -lactide polymer that is absorbed after approximately 2 years via the Krebs cycle .A prospective , open - label , 2-stage study called ABSORB including 131 patients was conducted in Europe and New Zealand and led to its approval by the EU in January 2011 for the treatment of coronary artery lesions [ 14 ] .", "label": "", "metadata": {}, "score": "92.891655"}
{"text": "Provisional stenting was permitted according to the following specific criteria : . a ) .Major dissection ( grade C or above ) .However , in order to limit stenting as much as possible , prolonged standard PTA ( 3 min ) with a non - drug - eluting balloon was to be performed first .", "label": "", "metadata": {}, "score": "93.25415"}
{"text": "In total a maximum of 4 stents may be implanted to fully cover the maximum of 2 target lesions per subject ; .Guidewire must be across the first ( if applicable ) target lesion and located intraluminally within the distal vessel before study randomization ; .", "label": "", "metadata": {}, "score": "93.42293"}
{"text": "Methods and results : A group of 814 consecutive patients undergoing percutaneous coronary intervention ( PCI ) was enrolled between 2007 and 2010 , of which 527 were treated with EES and 287 with BES implantation .", "label": "", "metadata": {}, "score": "93.73423"}
{"text": "We find that it is possible to ablate plaque just below the surface without causing surface damage , which motivates further investigation of ultrafast ablation for subsurface atherosclerotic plaque removal .", "label": "", "metadata": {}, "score": "93.84663"}
{"text": "[ Time Frame : 12 months ] [ Designated as safety issue : No ] .[ Time Frame : post procedure ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "93.86577"}
{"text": "New technology has also provided a potential improvement over current modalities of therapy .Unfortunately , these fundamental \" patient - centric \" endpoints and essential post - treatment care and follow - up are infrequently pre - specified and/or are incompletely monitored and reported in CLI trials .", "label": "", "metadata": {}, "score": "94.0658"}
{"text": "Before the initiation of the interventional procedure , a 55-cm radiopaque ruler was affixed to the index extremity extending from tibial tuberosity to the level of the lateral malleolus .", "label": "", "metadata": {}, "score": "94.3336"}
{"text": "Wound status of index limb ( if applicable ) due to CLI measured by digital photography , depth / length / width measurements , infection and wound closure status .", "label": "", "metadata": {}, "score": "94.39164"}
{"text": "Wound status of index limb ( if applicable ) due to CLI measured by digital photography , depth / length / width measurements , infection and wound closure status .", "label": "", "metadata": {}, "score": "94.39164"}
{"text": "Written informed consent prior to any study procedures .Exclusion Criteria : .Angiographic evidence of thrombus within target vessel ; .Thrombolysis within 72 hours prior to the index procedure ; .", "label": "", "metadata": {}, "score": "94.41086"}
{"text": "[ Time Frame : post procedure ] [ Designated as safety issue : No ] .Procedural Complications defined as any adverse event from the time of arterial punction up to the moment of catheter sheath removal or subject leaving the cath lab , whichever is earlier .", "label": "", "metadata": {}, "score": "94.713745"}
{"text": "[ Time Frame : post procedure ] [ Designated as safety issue : No ] .Procedural Complications defined as any adverse event from the time of arterial punction up to the moment of catheter sheath removal or subject leaving the cath lab , whichever is earlier .", "label": "", "metadata": {}, "score": "94.713745"}
{"text": "Known or suspected active infection at the time of the index procedure , excluding an infection of a lower extremity wound of the target limb ; .", "label": "", "metadata": {}, "score": "94.94656"}
{"text": "The 5-year follow - up of patients in EXCELLA II marks the completion of the EXCELLA II randomized controlled trial .Elixir 's DESyne Novolimus Eluting Coronary Stent System is commercially available in countries in Europe , Middle - East and Asia .", "label": "", "metadata": {}, "score": "94.99895"}
{"text": "In the NEVO RES I trial , patients completed the questionnaire when they were initially randomized and then one and six months after treatment .\" While these are preliminary findings that need further confirmation , this study is significant because it is the first time we have begun including patient - reported outcomes into device trials .", "label": "", "metadata": {}, "score": "95.01755"}
{"text": "The principal investigator is continuously informed by the DSMB and CAEC and is , by not being blinded , solely responsible for trial halting .Discussion .", "label": "", "metadata": {}, "score": "95.145515"}
{"text": "As this sample size is larger than the intended enrollment for the trial , the power for this endpoint in the current trail based upon intended sample size of 357 is 65 % rather than 80 % .", "label": "", "metadata": {}, "score": "95.31288"}
{"text": "Revascularisation procedures such as percutaneous coronary intervention are associated with overall worse outcomes in patients with diabetes mellitus .Implantation of coronary stents is associated with higher restenosis rates compared to non - diabetic individuals .", "label": "", "metadata": {}, "score": "95.32204"}
{"text": "TL : .Target lesion .TLR : .Target lesion revascularization .UADE : .Unanticipated adverse device effect .US IDE : .United States investigational device exemption .", "label": "", "metadata": {}, "score": "95.497986"}
{"text": "Subjects who failed angiographic and procedural eligibility criteria were considered \" screen failures \" .The screen failures were not considered as enrolled subjects for the purposes of intent - to - treat ( ITT ) analysis .", "label": "", "metadata": {}, "score": "95.6507"}
{"text": "Its non - inferiority to the Xience Prime ( Abbott Vascular ) , an EES , is currently under investigation in the international ABSORB EXTEND trial that plans to enroll 1,000 patients ( NCT01023789 ) .", "label": "", "metadata": {}, "score": "95.68083"}
{"text": "To address these issues , the IN.PACT DEEP trial will evaluate the impact of direct vs. indirect revascularization and the number of revascularized vessels on wound healing and limb salvage .", "label": "", "metadata": {}, "score": "95.7045"}
{"text": "Allocation concealment will be kept in sealed envelopes containing a non - transparent pleated color sheet in which the etiquette for intervention is embedded .The investigator is responsible for enrolment and a study nurse will assign participants to either stent implantation .", "label": "", "metadata": {}, "score": "95.79866"}
{"text": "Conclusions : This first clinical study failed to demonstrate any significant difference regarding safety or efficacy between these two types and generations of drug - eluting stents ( DES ) .", "label": "", "metadata": {}, "score": "95.97152"}
{"text": "Intervention : Device : drug eluting stent .Not Provided .Recruitment Information .Recruitment Status ICMJE .Completed .Enrollment ICMJE .Completion Date .", "label": "", "metadata": {}, "score": "96.20799"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00368953 [ Show abstract ] [ Hide abstract ] ABSTRACT : BACKGROUND : Head - to - head optical coherence tomography ( OCT ) data comparing metallic stents with bioresorbable vascular scaffolds ( BVS ) are lacking .", "label": "", "metadata": {}, "score": "96.28606"}
{"text": "PubMed View Article .Schmidt A , Ulrich M , Winkler B , Klaeffling C , Bausback Y , Br\u00e4unlich S , Botsios S , Kruse HJ , Varcoe RL , Kum S , Scheinert D : Angiographic patency and clinical outcome after balloon - angioplasty for extensive infrapopliteal arterial disease .", "label": "", "metadata": {}, "score": "96.770454"}
{"text": "PubMed View Article .Graziani L , Silvestro A , Bertone V , Manara E , Andreini R , Sigala A , Mingardi R , De Giglio R : Vascular involvement in diabetic subjects with ischemic foot ulcer : a new morphologic categorization of disease severity .", "label": "", "metadata": {}, "score": "97.19597"}
{"text": "Optical coherence tomography ( OCT ) is conducted in the first 30 patients of each group willing to undergo the aforementioned procedure .Percentage of malapposed struts , frequency of abnormal intrastent tissue , frequency of peristrut low intensity area and percent net volume obstruction will be assessed with the use of automated edge - detection system ( Illumien - optis ORW , St. Jude Medical , St. Paul , MN , USA ) .", "label": "", "metadata": {}, "score": "97.216675"}
{"text": "Sublingual nitroglycerin was associated with maximal vasodilatation of the peristent segments in both groups .Conclusion : Alike DES with durable polymer , stents with a biodegradable polymer are associated with exercise - induced paradoxical coronary vasoconstriction of the peristent segments .", "label": "", "metadata": {}, "score": "97.52429"}
{"text": "10.1016/j.jacc.2006.03.042 View Article PubMed .Kedhi E , Joesoef KS , McFadden E , Wassing J , van Mieghem C , Goedhart D , Smits PC : Second - generation everolimus - eluting and paclitaxel - eluting stents in real - life practice ( COMPARE ) : a randomised trial .", "label": "", "metadata": {}, "score": "97.7717"}
{"text": "Primary safety endpoint .After 10 % potential attrition relative to this endpoint , the required sample size is 357 ( with 238 expected in the IA - DEB group and 119 in the PTA group ) .", "label": "", "metadata": {}, "score": "98.27261"}
{"text": "The primary outcome is analyzed using a parametric or nonparametric test according to distribution and by the computation of a multivariate linear analysis by taking into account significant risk factors that potentially influence outcome thus adjusting for them .", "label": "", "metadata": {}, "score": "98.29802"}
{"text": "The subject is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study .", "label": "", "metadata": {}, "score": "98.368164"}
{"text": "The recruitment phase is complete as of November 2013 .Declarations .Acknowledgements .This study was funded by the Fonds Scientifique Cardiovasculaire , Fribourg , Switzerland .", "label": "", "metadata": {}, "score": "98.67844"}
{"text": "The unresolved problem of neointimal proliferation and very late stent thrombosis from lingering polymers and vascular scaffolds , led to the development of new - generation completely resorbable stents .", "label": "", "metadata": {}, "score": "98.90733"}
{"text": "Trial registration .Keywords .Peripheral vascular disease Critical limb ischemia Infrapopliteal Drug - eluting balloon .Background .Several studies established lower peri - procedural mortality and morbidity and high technical success for PTA , leading some centers to consider infrapopliteal artery angioplasty , particularly in specific high - risk CLI patient cohorts , to be the \" first line \" therapeutic approach [ 4 - 7 ] .", "label": "", "metadata": {}, "score": "98.96671"}
{"text": "10.1016/j.jacc.2006.10.049 View Article PubMed .Joner M , Finn AV , Farb A , Mont EK , Kolodgie FD , Ladich E , Kutys R , Skorija K , Gold HK , Virmani R : Pathology of drug - eluting stents in humans : delayed healing and late thrombotic risk .", "label": "", "metadata": {}, "score": "99.15503"}
{"text": "Both .Ages .18 Years to 85 Years .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects .", "label": "", "metadata": {}, "score": "99.255295"}
{"text": "SAEs include AEs of categories 3 - 5 and include any untoward medical occurrence in a subject which : .Led to a death or .", "label": "", "metadata": {}, "score": "99.45769"}
{"text": "PubMed View Article .Manzi M , Fusaro M , Ceccacci T , Erente G , Dalla Paola L , Brocco E : Clinical results of below - the knee intervention using pedal - plantar loop technique for the revascularization of foot arteries .", "label": "", "metadata": {}, "score": "99.68224"}
{"text": "Standard interventional techniques in crossing arterial stenoses and/or occlusions were to be employed ; re - entry devices in the infrapopliteal segment were contraindicated .Pre - dilatation with an undersized ( non - drug - eluting ) balloon were required in case of total occlusions and sub - occlusive lesions ; however , adjuncts to angioplasty , including atherectomy , cutting or scoring balloons were not permitted .", "label": "", "metadata": {}, "score": "99.799255"}
{"text": "Trial interruption .The trial will be halted should the incidence of clinical endpoints significantly differ between the different devices during the intermediate analysis .The trial will also be halted should the incidence of adverse clinical events exceed the expected values at any point .", "label": "", "metadata": {}, "score": "99.830826"}
{"text": "Development stage products include the Combo Dual Therapy Stent , the only dual therapy stent to both accelerate endothelial coverage and control neo - intimal proliferation through the combination of the Genous pro - healing technology with an abluminal sirolimus drug elution .", "label": "", "metadata": {}, "score": "99.938835"}
{"text": "Subjects .One hundred sixty - seven of these subjects were allocated to the Angio cohort ( 113 subsequently randomized to IA - DEB and 54 to PTA ) and the remaining 191 to the Clinical cohort ( 126 subsequently randomized to IA - DEB and 65 to PTA ) .", "label": "", "metadata": {}, "score": "99.942"}
{"text": "10.1161/CIRCULATIONAHA.110.971606 View Article PubMed .Gogas BD , Farooq V , Onuma Y , Serruys PW : The ABSORB bioresorbable vascular scaffold : an evolution or revolution in interventional cardiology ?", "label": "", "metadata": {}, "score": "100.068344"}
{"text": "If the patient is not accessible , data can be retrieved from the referring physician or the hospital electronic database .Statistical analyses .We plan to enroll 80 patients in each group .", "label": "", "metadata": {}, "score": "100.172935"}
{"text": "( B ) General exclusion criteria .e.1 Patient unwilling or unlikely to comply with follow - up schedule .e.2 Planned major index limb amputation .", "label": "", "metadata": {}, "score": "100.23213"}
{"text": "Puricel S , Oberh\u00e4nsli M , Guntern P , Lehmann S , Goy JJ , Arroyo D , Villeneuve H , Baeriswyl G , Stauffer JC , Togni M , Cook S : Long - term comparison of everolimus - eluting and biolimus - eluting stents .", "label": "", "metadata": {}, "score": "100.28724"}
{"text": "PubMed View Article .Iida O , Nanto S , Uematsu M , Ikeoka K , Okamoto S , Dohi T , Fujita M , Terashi H , Nagata S : Importance of the angiosome concept for endovascular therapy in patients with critical limb ischemia .", "label": "", "metadata": {}, "score": "100.288506"}
{"text": "Recently , the randomized COMPARE II trial enrolling 2,707 patients , confirmed the BES safety but no differences were observed in clinical endpoints at 2-year follow - up when compared to EES [ 12 ] .", "label": "", "metadata": {}, "score": "100.885315"}
{"text": "SC conceived and designed the research , made critical revision of the manuscript for important intellectual content and handled funding and supervision .The authors read and approved the final manuscript .", "label": "", "metadata": {}, "score": "101.00586"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Coronary heart disease affects 2 - 6 % of the general population ; in the USA , it is responsible for more than 400,000 deaths each year .", "label": "", "metadata": {}, "score": "101.00886"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : The first CE - approved bioresorbable vascular scaffold ( BVS ) is effective at treating simple lesions and stable coronary artery disease , but it has yet to be assessed versus the best - in - class drug - eluting stents ( DES ) .", "label": "", "metadata": {}, "score": "101.08501"}
{"text": "If all requirements were not documented , the subject was considered a screen failure .After documentation of the above requirements , if the subject was randomized to the investigational treatment , the IA - DEB balloon of a diameter approximating a 1:1 ratio to the reference artery diameter was deployed and inflated for a minimum of 1 min .", "label": "", "metadata": {}, "score": "101.15461"}
{"text": "Approach to the tibial artery target lesion was contralateral retrograde or ipsilateral antegrade .Accessing the target lesion ( TL ) from the popliteal or pedal approach was contraindicated .", "label": "", "metadata": {}, "score": "101.485306"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Background : Drug - eluting stents ( DES ) have been associated with local endothelial dysfunction in the segments proximal and distal to the stent ( peristent segments ) and increased thrombotic risk in long term follow - up .", "label": "", "metadata": {}, "score": "101.74521"}
{"text": "Subjects who met certain specific additional inclusion and exclusion criteria ( see Figure 1 and Table 1 F and G ) were allocated to the Angio cohort .", "label": "", "metadata": {}, "score": "101.99411"}
{"text": "Single treatment of de novo or restenotic ( after PTA only ) lesion(s ) in the tibioperoneal trunk , anterior and/or posterior tibial and/or peroneal artery ; .", "label": "", "metadata": {}, "score": "102.06856"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Background : It is inferred that interventional cardiologists may be immune to stress allowing them to perform complex percutaneous interventions under pressure .", "label": "", "metadata": {}, "score": "102.14827"}
{"text": "The biodegradable polymer used to contain and release Sirolimus facilitates rapid endothelialization and results of pre - clinical studies indicated no greater inflammation than seen with bare metal stents .", "label": "", "metadata": {}, "score": "102.26712"}
{"text": "PubMed .Kabra A , Suresh K , Vivekanand V , Vishnu M , Sumanth R , Nekkanti M : Outcomes of angiosome and non - angiosome targeted revascularization in critical lower limb ischemia .", "label": "", "metadata": {}, "score": "102.28644"}
{"text": "In order to set up this optimisation process , the clinical practice for a given cardiology centre has to be analysed with relevant statistical power and compared with the data at local or national level .", "label": "", "metadata": {}, "score": "102.4957"}
{"text": "Kelsch B , Scheller B , Biedermann M , Clever YP , Schaffner S , Mahnkopf D , Speck U , Cremers B : Dose response to Paclitaxel - coated balloon catheters in the porcine coronary overstretch and stent implantation model .", "label": "", "metadata": {}, "score": "102.61162"}
{"text": "- Give general information about radiation protection .DISCUSSION As radiation - induced erythema occur several days or weeks the X - ray exposure , it can be easily diagnosed as being caused by another factor , such as medication or allergy .", "label": "", "metadata": {}, "score": "102.96121"}
{"text": "The Genous Stent , which has been commercially available in more than 60 countries since 2005 , has been proven as a safe , effective alternative to drug eluting stents and is supported by data from more than 7,000 patients in company - sponsored clinical studies .", "label": "", "metadata": {}, "score": "103.18077"}
{"text": "Study Type ICMJE .Interventional .Study Phase .Phase 4 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "103.43543"}
{"text": "Participants were asked to record their HR with the Apple Watch Device during procedures , every - day life and control activities such as outpatient consultations , sport , marital conflicts and sexual intercourse .", "label": "", "metadata": {}, "score": "103.69369"}
{"text": "The collected dose indicators were , when available , cumulated air kerma , cumulated dose - area product , fluoroscopy time and the number of images per procedure .", "label": "", "metadata": {}, "score": "103.86656"}
{"text": "NEVO ?Sirolimus - Eluting Coronary Stent Associated with Significantly Less Chest Pain at Six Months Than Taxus Liberte Stent .Quality - of - Life Data , a First for a Drug - Eluting Stent , Presented at TCT 09 .", "label": "", "metadata": {}, "score": "104.20897"}
{"text": "BES is a metallic stent that uses an abluminal bioresorbable polymer coating .This polymer is completely converted to lactic acid by 6 months and , via the Krebs cycle , to carbon dioxide and water by 6 to 9 months .", "label": "", "metadata": {}, "score": "104.27506"}
{"text": "All members of the CEAC are blinded to the primary results of the trial .The study complies with the Declaration of Helsinki and was approved by the local ethics committee of Fribourg University and Hospital ( Switzerland , 043/12-CER - FR ) .", "label": "", "metadata": {}, "score": "104.298744"}
{"text": "Index percutaneous coronary intervention .Procedures will be performed via the femoral or radial artery with a 5 - 6 French ( F ) guiding catheter .", "label": "", "metadata": {}, "score": "104.31235"}
{"text": "( E ) General procedural exclusion criteria .DES and/or DEB was not allowed for the treatment of inflow lesions .e.11 Use of alternative therapy , e.g. , atherectomy , cutting balloon , laser , radiation therapy , DES as part of the index procedure .", "label": "", "metadata": {}, "score": "104.434006"}
{"text": "PubMed View Article .Werk M , Langner S , Reinkensmeier B , Boettcher HF , Tepe G , Dietz U , Hosten N , Hamm B , Speck U , Ricke J : Inhibition of restenosis in femoropopliteal arteries : paclitaxel - coated versus uncoated balloon : femoral paclitaxel randomized pilot trial .", "label": "", "metadata": {}, "score": "104.46428"}
{"text": "Written informed consent will be obtained as required by the local institutional ethics committee in accordance with the Declaration of Helsinki .Treatment assignment .Patient randomization will be performed after lesion preparation .", "label": "", "metadata": {}, "score": "104.58284"}
{"text": "The aim of our study was to compare the local endothelial function assessed by exercise induced coronary vasomotion after implantation of a biolimus A9-eluting stent with biodegradable polymer ( BES ) with an everolimus - eluting stent with durable polymer ( EES ) .", "label": "", "metadata": {}, "score": "105.47755"}
{"text": "Objectives : To assess heart rate ( HR ) variations as a surrogate marker of stress of interventional cardiologists during percutaneous cardiac procedures and in every - day life .", "label": "", "metadata": {}, "score": "105.506355"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Aims : To compare clinical outcome of Amplatzer PFO ( APFO ) to Cardia PFO ( CPFO ) occluder .", "label": "", "metadata": {}, "score": "105.62557"}
{"text": "Alterations in regional pedal circulation impact successful healing in patients with ischemic ulcers [ 25 , 26 ] .Regional perfusion differences may be accentuated if the source or wound - related artery ( WRA ) to the ischemic angiosome is occluded and collateral vessels perfuse the impacted angiosome indirectly .", "label": "", "metadata": {}, "score": "105.64737"}
{"text": "To view content sources and attributions , please refer to our editorial policy .Current Secondary Outcome Measures ICMJE ( submitted : December 6 , 2010 ) .", "label": "", "metadata": {}, "score": "105.661804"}
{"text": "Conclusion .The IN.PACT DEEP represents the first completed , largest , prospective , multicenter , randomized , controlled comparison of plain old balloon angioplasty to drug - eluting balloon angioplasty in infrapopliteal arteries of patients with CLI .", "label": "", "metadata": {}, "score": "106.28349"}
{"text": "The subject is currently taking Coumarin / Warfarin which , in the opinion of the investigator , interferes with the subject 's participation in the study ; .", "label": "", "metadata": {}, "score": "106.33934"}
{"text": "Atherosclerotic plaque growth proceeds from the accumulation of fatty deposits , cholesterol , and cellular waste products in the inner layer of the coronary arteries .", "label": "", "metadata": {}, "score": "106.36361"}
{"text": "Design : This is a single - centre observational study including a total of 6 male interventional cardiologists performing coronary interventions and pacemaker implantations .Participants were asked to record their heart rate ( HR ) via the Apple Watch Device during procedures , every - day life and control activities such as outpatient consultations , sport , marital conflicts and sexual intercourse .", "label": "", "metadata": {}, "score": "106.4903"}
{"text": "10.1016/j.jacc.2005.02.086 View Article PubMed .Circulation 2006 , 113 : 1108 - 1113 .10.1161/CIRCULATIONAHA.105.600155 View Article PubMed .Cook S , Wenaweser P , Togni M , Billinger M , Morger C , Seiler C , Vogel R , Hess O , Meier B , Windecker S : Incomplete stent apposition and very late stent thrombosis after drug - eluting stent implantation .", "label": "", "metadata": {}, "score": "107.04486"}
{"text": "As for the staff , it will help them with their daily practice by giving them useful tips aiming to reduce the dose delivered to the patient and , as a consequence , their own personal dose .", "label": "", "metadata": {}, "score": "107.203354"}
{"text": "In .PACT DEEP completed subject enrollment / randomization in July 2012 , and the final enrolled subjects returned for clinical follow - up in August 2013 .", "label": "", "metadata": {}, "score": "107.22696"}
{"text": "Responsible Party .Hans - Peter Stoll - MD , PhD - Worldwide VP Clinical Research & Operations , Cordis", "label": "", "metadata": {}, "score": "107.29921"}
{"text": "Drug - eluting stents ( DES ) have considerably reduced neointimal hyperplasia and significantly decreased the risk of restenosis compared to bare metal stents ( BMS ) [ 1 ] .", "label": "", "metadata": {}, "score": "107.39694"}
{"text": "Methods / Design .The EVERBIO II trial is a single - center , assessor - blinded , randomized trial .A total of 240 patients will be enrolled and randomly assigned into 3 groups of 80 with either BVS , EES or BES implantation .", "label": "", "metadata": {}, "score": "107.647156"}
{"text": "Aneurysm in the SFA or popliteal artery ; .Requiring popliteal arterial access ; .Concomitant hepatic insufficiency , thrombophlebitis , deep venous thrombus , coagulation disorder or receiving immunosuppressant therapy ; .", "label": "", "metadata": {}, "score": "107.86304"}
{"text": "Methods / design : The EVERBIO II trial is a single - center , assessor - blinded , randomized trial .A total of 240 patients will be enrolled and randomly assigned into 3 groups of 80 with either BVS , EES or BES implantation .", "label": "", "metadata": {}, "score": "107.86842"}
{"text": "Authors ' contributions .DA drafted this manuscript .SP performed the statistical planning .SJ , HV , EB and NC participated in data acquisition .", "label": "", "metadata": {}, "score": "108.50952"}
{"text": "All authors approved the final manuscript .Authors ' Affiliations .Department of Angiology , Universit\u00e4ts Herzzentrum Freiburg Bad Krozingen .Swiss Cardiovascular Center , Division of Angiology , University Hospital , Inselspital .", "label": "", "metadata": {}, "score": "108.66051"}
{"text": "Wound - related artery .Declarations .Acknowledgements .Funding .Medtronic , Inc. ( Santa Rosa , CA , USA ) funded the IN.PACT DEEP Trial .", "label": "", "metadata": {}, "score": "108.73162"}
{"text": "AEs will be assessed and documented by the site investigators at the time of the procedure and at all follow - up visits ( scheduled and unscheduled ) .", "label": "", "metadata": {}, "score": "109.26152"}
{"text": "10.1016/j.jacc.2011.01.023 View Article PubMed .Circ Cardiovasc Interv 2009 , 2 : 188 - 195 .10.1161/CIRCINTERVENTIONS.108.823443 View Article PubMed .Lancet 2011 , 378 : 1940 - 1948 .", "label": "", "metadata": {}, "score": "109.26582"}
{"text": "BES : biolimus - eluting stent , BVS : biovascular scaffold , EES : everolimus - eluting stent , OCT : optical coherence tomography , PCI : percutaneous coronary intervention .", "label": "", "metadata": {}, "score": "109.42254"}
{"text": "Study Arm ( s ) .Active Comparator : balloon angioplasty .balloon angioplasty .Intervention : Device : balloon angioplasty .Experimental : Drug eluting stent .", "label": "", "metadata": {}, "score": "109.50594"}
{"text": "7 Wound assessment performed via the SilhouetteMobile . 8 Only Wound Care .Data collection .Data will be collected via e - CRF during treatment at all investigational centers and will be completed prospectively during the hospital admission and follow - up .", "label": "", "metadata": {}, "score": "109.59483"}
{"text": "A literature review is presented of the current status of endovascular treatment of CLI with drug - eluting balloon and standard PTA .The rationale and design of the IN.PACT DEEP Trial are discussed .", "label": "", "metadata": {}, "score": "109.81087"}
{"text": "Polylactide - containing stents ( BVS and BES ) demonstrate lower peristrut intensity compared with EES .Full - text \u00b7 Article \u00b7 Jan 2016 \u00b7 Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases , the Swiss Society of Internal Medicine , the Swiss Society of Pneumology .", "label": "", "metadata": {}, "score": "110.48218"}
{"text": "We seek to compare the efficacy and safety profiles of these three different types and generations of DES .Study objectives and hypothesis .The null hypothesis to be rejected is that all three stents are of equal efficacy .", "label": "", "metadata": {}, "score": "110.73074"}
{"text": "Circulation 2006 , 113 ( 11):e463-e654 .PubMed View Article .Conte MS : Diabetic revascularization : endovascular versus open bypass - do we have the answer ?", "label": "", "metadata": {}, "score": "111.06671"}
{"text": "Quality - of - life data from the NEVO RES I trial were released today at the Transcatheter Cardiovascular Therapeutics ( TCT ) 2009 , the largest gathering of physicians focused specifically on interventional vascular treatments .", "label": "", "metadata": {}, "score": "111.0773"}
{"text": "No other extramural funding was used to support this work .Competing interests .SC has received educational grants from Abbott Vascular , Biosensors International and Boston Scientific .", "label": "", "metadata": {}, "score": "111.6057"}
{"text": "The EVERBIO II ( Comparison of Everolimus- and Biolimus - Eluting Stents With Everolimus - Eluting Bioresorbable Vascular Scaffold Stents II ) trial was a single - center , assessor - blinded study of 240 patients randomly assigned in a 1:1:1 ratio to EES , BES , or BVS .", "label": "", "metadata": {}, "score": "111.64529"}
{"text": "New analyses from the REMEDEE trial were also presented at ACC.12 and compared angiographic and intravascular ultrasound ( IVUS ) endpoints for the Combo Dual Therapy Stent versus the TAXUS \u00ae Liberte \u00ae paclitaxel - eluting stent .", "label": "", "metadata": {}, "score": "112.15773"}
{"text": "PubMed View Article .J Am Coll Cardiol 2011 , 58 ( 11):1105 - 1109 .PubMed View Article .Fanelli F , Cannavale A , Boatta E , Corona M , Lucatelli P , Wlderk A , Cirelli C , Salvatori FM : Lower limb multilevel treatment with drug - eluting balloons : 6-month results from the DEBELLUM randomized trial .", "label": "", "metadata": {}, "score": "112.22039"}
{"text": "Elixir Medical Announces Outstanding Long - Term Clinical Results at EuroPCR for World 's Broadest Portfolio of Three CE Mark - Approved Novolimus Eluting Coronary Intervention Systems .", "label": "", "metadata": {}, "score": "112.237656"}
{"text": "Occlusive complication ( e.g. , recoil ) that resulted in severely decreased target vessel flow that did not respond to repeated prolonged balloon inflation .c ) .", "label": "", "metadata": {}, "score": "112.42296"}
{"text": "The organization and scientific conduct is supervised by a Steering Committee .A Data and Safety Monitoring Board is responsible for safety and ethical aspects .", "label": "", "metadata": {}, "score": "113.2168"}
{"text": "a. .resulted in a life - threatening illness or injury , and/or .b. . resulted in a permanent impairment of a body structure or body function , and/or .", "label": "", "metadata": {}, "score": "113.34845"}
{"text": "Published by Elsevier Inc.All rights reserved .Full - text \u00b7 Article \u00b7 Mar 2015 \u00b7 Journal of the American College of Cardiology .We present the first study to provide a 10-year clinical follow - up in an unselected patient population who underwent SES implantation .", "label": "", "metadata": {}, "score": "113.497215"}
{"text": "Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease .", "label": "", "metadata": {}, "score": "113.65721"}
{"text": "- Estimate the risk and severity of potential radiation - induced skin burns and the necessity of patient follow - up .- Estimate one 's average personal dose .", "label": "", "metadata": {}, "score": "113.74412"}
{"text": "EuroPCR 2014 .Outstanding 18-month results of Elixir 's CE Mark - approved DESolve \u00ae Novolimus Eluting Bioresorbable Coronary Scaffold System were also presented at the annual EuroPCR conference in Paris .", "label": "", "metadata": {}, "score": "113.89446"}
{"text": "Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "114.11376"}
{"text": "BACKGROUND The number and complexity of interventional radiology and cardiology ( IR / IC ) procedures has been steadily increasing over the last twenty years .", "label": "", "metadata": {}, "score": "114.21925"}
{"text": "10.1053/euhj.2001.2892 View Article PubMed .N Engl J Med 2002 , 346 : 1773 - 1780 .10.1056/NEJMoa012843 View Article PubMed .", "label": "", "metadata": {}, "score": "114.36109"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Second - generation everolimus - eluting stents ( EES ) and third generation biolimus - eluting stents ( BES ) have been shown to be superior to first - generation paclitaxel - eluting stents ( PES ) and second - generation sirolimus - eluting stents ( SES ) .", "label": "", "metadata": {}, "score": "114.50666"}
{"text": "The Absorb \u2122 BVS is the first , fully bioresorbable coronary scaffold to have been launched for clinical use with CE approval .It uses a poly- l -lactide polymer that undergoes a four - stage bioresorption through hydration , depolymerization , polymer fragmentation and dissolution over 2 years via the Krebs cycle [ 26 ] .", "label": "", "metadata": {}, "score": "114.64158"}
{"text": "Extent of infrapopliteal revascularization and wound healing .The angiosome concept , introduced by Taylor et al .[ 24 ] , is an anatomic unit of tissue , fascia , muscle , and bone fed by a source artery and drained by specific veins .", "label": "", "metadata": {}, "score": "115.08741"}
{"text": "The EVERBIO II trial will assess BVS efficacy compared to the latest DES on the market in all patients viable for inclusion experiencing more complex lesions and clinical situations .", "label": "", "metadata": {}, "score": "115.12674"}
{"text": "Third - generation biolimus - eluting stents ( BES ) have been found to be non - inferior to PES .To date , there is no available comparative study between EES and BES .", "label": "", "metadata": {}, "score": "115.280106"}
{"text": "Elixir 's DESyne Stent elutes the novel m - tor inhibitor compound , Novolimus .It is the first drug eluting stent to successfully combine the thinnest durable polymer coating , the lowest drug dose , and thin stent struts to achieve excellent clinical outcomes as compared to other commercially available drug eluting stent systems .", "label": "", "metadata": {}, "score": "115.33366"}
{"text": "AM and TZ are consultants for Medtronic ; FM receives grant support from Medtronic .DS and ML are Medtronic employees .All other authors have nothing to disclose .", "label": "", "metadata": {}, "score": "115.375496"}
{"text": "The AbsorbTM ( Abbott Vascular , Abbott Park , IL , USA ) is the first CE approved DES with a bioresorbable vascular scaffold ( BVS ) thought to reduce long - term complication rates .", "label": "", "metadata": {}, "score": "115.41374"}
{"text": "Continuous variables are presented as mean \u00b1 standard deviation or median ( 25 % to 75 % ) interquartile range according to their distribution .Categorical variables are presented as counts and percentages .", "label": "", "metadata": {}, "score": "115.53231"}
{"text": "Binary logistic regression is equally performed in the search of independent predictors for the secondary endpoints .All analyses are performed according to the intention - to - treat principle .", "label": "", "metadata": {}, "score": "115.539764"}
{"text": "PubMed View Article .Taylor G , Palmer J : The vascular territories ( angiosomes ) of the body : experimental studies and clinical application .", "label": "", "metadata": {}, "score": "115.6918"}
{"text": "No preview \u00b7 Article \u00b7 Jul 2015 \u00b7 EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology .", "label": "", "metadata": {}, "score": "115.74712"}
{"text": "ARIAD licensed ridaforolimus to Medinol for use in drug - eluting stents in 2005 .Drug - eluting stents ( DES ) are now implanted in over 500,000 patients yearly in the United States .", "label": "", "metadata": {}, "score": "116.15322"}
{"text": "Everolimus - eluting stents ( EES ) and biolimus - eluting stents ( BES ) are more recent DES that have been widely investigated .The EES is at present the most frequently used DES in the USA and in Europe [ 3 ] .", "label": "", "metadata": {}, "score": "116.72352"}
{"text": "This kind of large - scale analysis could yield some onsets towards local practice optimisation based on anonymous dose indicator cross - comparison .Further effort should nevertheless be made in order to proceed towards an operator - based data analysis , thus allowing for an individual practice optimisation .", "label": "", "metadata": {}, "score": "116.89259"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00472472 .Peripheral Arterial Disease Peripheral Vascular Diseases Arterial Occlusive Diseases Arteriosclerosis Atherosclerosis Cardiovascular Diseases Vascular Diseases Paclitaxel .", "label": "", "metadata": {}, "score": "116.91313"}
{"text": "10.1056/NEJMoa0910496 View Article PubMed .J Am Coll Cardiol 2011 , 58 : 1325 - 1331 .10.1016/j.jacc.2011.06.027 View Article PubMed .", "label": "", "metadata": {}, "score": "117.06867"}
{"text": "c Usual laboratory survey include , complete blood count , electrolytes , fasting glucose level , INR , prothrombin time , partial thromboplastin time , creatinine , blood urea nitrogen , pregnancy test if applicable .", "label": "", "metadata": {}, "score": "117.12987"}
{"text": "Elixir also announced excellent long - term results of its CE Mark - approved DESyne \u00ae BD Novolimus Eluting Coronary Stent System with biodegradable polymer coating compared to the control Endeavor Zotarolimus Eluting Coronary Stent System with durable coating in the EXCELLA BD randomized clinical trial at the 3-year endpoint .", "label": "", "metadata": {}, "score": "117.45811"}
{"text": "New - generation metallic DES ( EES / BES ) were not superior to BVS in terms of angiographic LLL and clinical outcomes .( Comparison of Everolimus- and Biolimus - Eluting Stents With Everolimus - Eluting Bioresorbable Vascular Scaffold Stents [ EVERBIO II ] ; NCT01711931 ) .", "label": "", "metadata": {}, "score": "117.61609"}
{"text": "Adam DJ , Beard JD , Cleveland T , Bell J , Bradbury AW , Forbes JF , Fowkes FG , Gillepsie I , Ruckley CV , Raab G , Storkey H : BASIL trial participants .", "label": "", "metadata": {}, "score": "117.74409"}
{"text": "A Prospective , Randomized , Multicenter Comparison of Balloon Angioplasty and the Cypher Selecttm + Coronary and Infrapopliteal Stent in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease .", "label": "", "metadata": {}, "score": "117.76229"}
{"text": "10.1161/CIRCULATIONAHA.106.658237 View Article PubMed .Circulation 2009 , 120 : 391 - 399 .10.1161/CIRCULATIONAHA.109.854398 View Article PubMed .Onuma Y , Serruys PW : Bioresorbable scaffold : the advent of a new era in percutaneous coronary and peripheral revascularization ?", "label": "", "metadata": {}, "score": "117.88416"}
{"text": "Discussion .While the body of clinical experience involving the treatment of CLI continues to evolve rapidly , our knowledge and understanding of the many factors that impact treatment outcomes of this heterogeneous and complex disease state remain incomplete .", "label": "", "metadata": {}, "score": "118.136246"}
{"text": "10.1016/S0140 - 6736(09)62127 - 9 View Article PubMed .J Am Coll Cardiol 2011 , 58 : 1844 - 1854 .10.1016/j.jacc.2011.07.031 View Article PubMed .", "label": "", "metadata": {}, "score": "118.531815"}
{"text": "Nat Rev Cardiol 2012 , 9 : 79 - 90 .View Article .Lancet 2008 , 371 : 899 - 907 .10.1016/S0140 - 6736(08)60415 - 8 View Article PubMed .", "label": "", "metadata": {}, "score": "118.543175"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : The aim of this analysis was to compare the long - term safety and efficacy of the biodegradable polymer biolimus - eluting stent ( BES ) with that of the durable polymer everolimus - eluting stent ( EES ) .", "label": "", "metadata": {}, "score": "118.96394"}
{"text": "Abstract .Background .Second - generation everolimus - eluting stents ( EES ) and third generation biolimus - eluting stents ( BES ) have been shown to be superior to first - generation paclitaxel - eluting stents ( PES ) and second - generation sirolimus - eluting stents ( SES ) .", "label": "", "metadata": {}, "score": "119.33493"}
{"text": "The SAQ is one of several quality of life measures included in the NEVO RES I clinical trial .There was no difference between NEVO \u2122 and the Taxus \u00ae Liberte \u00ae Stent in the SAQ physical limitation or treatment satisfaction scales or the SF-12 Physical Component Score .", "label": "", "metadata": {}, "score": "119.50661"}
{"text": "About Cordis Corporation .For more than 50 years , Cordis Corporation , a Johnson & Johnson company , has been a worldwide leader in the development and manufacture of interventional vascular technology .", "label": "", "metadata": {}, "score": "119.762596"}
{"text": "10.1056/NEJMoa035071 View Article PubMed .N Engl J Med 2004 , 350 : 221 - 231 .10.1056/NEJMoa032441 View Article PubMed .", "label": "", "metadata": {}, "score": "119.94579"}
{"text": "Keywords .Biolimus - eluting stent Bioresorbable vascular scaffold ( BVS ) Coronary artery disease Drug - eluting stent Everolimus - eluting stent Late lumen loss Percutaneous coronary intervention .", "label": "", "metadata": {}, "score": "120.58269"}
{"text": "Paclitaxel Coated Balloon Catheter for Inhibition of Restenosis in Femoropopliteal Arteries ( PACCOCATH - FEM I ) .Background : Treatment of patients with peripheral arterial disease ( PAD ) in the femoropopliteal arteries by percutaneous intervention is still limited by high rates of restenosis .", "label": "", "metadata": {}, "score": "121.038994"}
{"text": "Other Study ID Numbers ICMJE .EE06 - 02 .Has Data Monitoring Committee .Yes .Plan to Share Data .Not Provided .IPD Description .", "label": "", "metadata": {}, "score": "121.27798"}
{"text": "Discussion .EVERBIO II is an independent , randomized study , aiming to compare the clinical efficacy , angiographic outcomes and safety of BVS , EES and BES in all comer patients .", "label": "", "metadata": {}, "score": "121.32014"}
{"text": "Radiation protection must thus become of prime importance and should be promoted by all possible means .EVALUATION We are developing a mobile application that will help the physician to evaluate his / her current state of practice regarding radiation protection .", "label": "", "metadata": {}, "score": "122.08732"}
{"text": "Ethics .This trial is conducted in accordance with the principles of the Declaration of Helsinki , ISO 14155 and Good Clinical Practices guidelines .The Ethics Committees of all investigational sites ( Table 3 ) approved the trial protocol , and written informed consent was obtained from all subjects before enrollment .", "label": "", "metadata": {}, "score": "122.1025"}
{"text": "Methods / Design .Study design and overview .This is a single center , assessor - blinded , randomized study comparing three different stents in de novo coronary lesions : the Absorb \u2122 , the Promus Element \u2122 and the Biomatrix Flex \u2122 .", "label": "", "metadata": {}, "score": "122.1212"}
{"text": "Sirolimus , the active drug released for the stent , is marketed by Wyeth Pharmaceuticals , a division of Wyeth , under the name Rapamune \u00ae .", "label": "", "metadata": {}, "score": "122.63548"}
{"text": "About the Genous Technology .Genous is OrbusNeich 's patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood - contact devices such as stents .", "label": "", "metadata": {}, "score": "123.22542"}
{"text": "Data from this trial will support a regulatory filing for a CE mark in countries outside the United States .About the NEVO \u2122 Sirolimus - eluting Coronary Stent .", "label": "", "metadata": {}, "score": "123.28682"}
{"text": "\" We are pleased to have one of the most innovative and successful medical device companies advance the development and potential commercialization of drug - delivery stents incorporating ridaforolimus , \" said Timothy P. Clackson , Ph.D. , president of research and development and chief scientific officer at ARIAD .", "label": "", "metadata": {}, "score": "123.362656"}
{"text": "OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries .About .Terms & Privacy .Connect .Subscribe to receive email notifications whenever new articles are published .", "label": "", "metadata": {}, "score": "123.647095"}
{"text": "Adverse and serious adverse events .Adverse events ( AEs ) are defined as any untoward medical occurrence in a subject whether or not considered related to the study device that is identified or worsens during the trial .", "label": "", "metadata": {}, "score": "124.09953"}
{"text": "Elixir products have become synonymous with dependable and excellent acute performance , and great long - term results , \" said Motasim Sirhan , Chief Executive Officer of Elixir Medical .", "label": "", "metadata": {}, "score": "124.406006"}
{"text": "Data sources include Micromedex \u00ae ( updated Jan 25th , 2016 ) , Cerner Multum \u2122 ( updated Feb 1st , 2016 ) , Wolters Kluwer \u2122 ( updated Feb 1st , 2016 ) and others .", "label": "", "metadata": {}, "score": "124.49391"}
{"text": "PubMed View Article .Circ Cardiovasc Interv 2012 , 5 ( 6):831 - 840 .PubMed View Article .Micari A , Cioppa A , Vadal\u00e0 G , Castriota F , Liso A , Marchese A , Grattoni C , Pantaleo P , Cremonesi A , Rubino P , Biamino G : 2-year results of paclitaxel - eluting balloons for femoropopliteal artery disease : evidence from a multicenter registry .", "label": "", "metadata": {}, "score": "124.77296"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : CONCLUSION The promotion of radiation protection must be done using all available means .The tremendous growth of mobile devices in the recent years called for a gap to be filled .", "label": "", "metadata": {}, "score": "124.985054"}
{"text": "EVERBIO II is an independent , randomized study , aiming to compare the clinical efficacy , angiographic outcomes and safety of BVS , EES and BES in all comer patients .", "label": "", "metadata": {}, "score": "125.00043"}
{"text": "ARIAD Pharmaceuticals , Inc. ( NASDAQ : ARIA ) and Medinol , Ltd. today announced the initiation of two registration trials of Medinol 's NIRsupreme TM Ridaforolimus - Eluting Coronary Stent System incorporating ARIAD 's mTOR inhibitor , ridaforolimus .", "label": "", "metadata": {}, "score": "125.02817"}
{"text": "Elixir Medical Corporation , a privately held company headquartered in Sunnyvale , California , develops products that combine state - of - the - art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide .", "label": "", "metadata": {}, "score": "126.59033"}
{"text": "\" The quality - of - life outcomes seen with NEVO \u2122 in this study are intriguing , \" said Campbell Rogers , M.D. , Chief Scientific Officer and Global Head , Research and Development , Cordis Corporation .", "label": "", "metadata": {}, "score": "127.69549"}
{"text": "The Absorb \u2122 ( Abbott Vascular , Abbott Park , IL , USA ) is the first CE approved DES with a bioresorbable vascular scaffold ( BVS ) thought to reduce long - term complication rates .", "label": "", "metadata": {}, "score": "127.76114"}
{"text": "Please click on the link within the confirmation email previously sent you to complete registration .Need a new registration confirmation email ?Click here .", "label": "", "metadata": {}, "score": "129.6806"}
{"text": "Methods / Design .IN.PACT DEEP is a 2:1 randomized controlled trial designed to assess the efficacy and safety of infrapopliteal arterial revascularization between the IN.PACT Amphirion \u2122 paclitaxel drug - eluting balloon ( IA - DEB ) and standard balloon angioplasty ( PTA ) in patients with Rutherford Class 4 - 5 - 6 CLI .", "label": "", "metadata": {}, "score": "130.31451"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "131.2139"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "131.2139"}
{"text": "IA - DEB manufactured by Medtronic ( Santa Rosa , CA , USA ) features a 0.014 \" guidewire - compatible , over - the - wire drug - eluting balloon that uses paclitaxel as the therapeutic agent and urea as excipient .", "label": "", "metadata": {}, "score": "132.40738"}
{"text": "An adverse device effect ( ADE ) is any untoward and unintended response to a medical device including any event resulting from insufficiencies or inadequacies in the instructions for use or the deployment of the device as well as any event that is a result of a user error .", "label": "", "metadata": {}, "score": "132.91898"}
{"text": "Department of Vascular Surgery , A.Z. Sint - Blasius .Invasive Cardioangiology GVM Care and Research .Department of Cardiovascular & Thoracic Surgery , Imelda Hospital .", "label": "", "metadata": {}, "score": "132.9837"}
{"text": "Follow BioMed Central .Trials main menu .IN.PACT Amphirion paclitaxel eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia : rationale and protocol for an ongoing randomized controlled trial .", "label": "", "metadata": {}, "score": "133.00385"}
{"text": "Official Title : .A Prospective , Randomized , Multicenter Comparison of the Drug - Eluting Stent Systems YUKON Choice and TAXUS Libert\u00e9 in Patients With Diabetes Mellitus .", "label": "", "metadata": {}, "score": "133.11655"}
{"text": "Ethikkommission , Univ .Prof .DI Dr. Haas , Aenbruggerplatz 2 , A-8036 Graz .Villa Maria Eleonora Hospital .Pr\u00e4sident der Ethik Kommission des Kantons Luzern , Luzerner Kantonspital , 6000 Lucerne 16 .", "label": "", "metadata": {}, "score": "134.2731"}
{"text": "About .Terms & Privacy .Connect .Subscribe to receive email notifications whenever new articles are published .This material is provided for educational purposes only and is not intended for medical advice , diagnosis or treatment .", "label": "", "metadata": {}, "score": "134.41672"}
{"text": "It is not yet approved or available for sale in any market .NEVO \u2122 also contains the same drug , Sirolimus , as the CYPHER \u00ae Sirolimus - eluting Coronary Stent , which has now been used in more than three million people worldwide .", "label": "", "metadata": {}, "score": "135.56824"}
{"text": "NEVO RES I Study Overview .The NEVO RES I study is a randomized , multi - center comparison of NEVO \u2122 to the Taxus \u00ae Liberte \u00ae Stent in de novo native coronary artery lesions .", "label": "", "metadata": {}, "score": "136.60689"}
{"text": "About OrbusNeich .OrbusNeich is a global company that designs , develops , manufactures and markets innovative medical devices for the treatment of vascular diseases .", "label": "", "metadata": {}, "score": "137.86522"}
{"text": "PubMed View Article .Schnorr B , Kelsch B , Cremers B , Clever YP , Speck U , Scheller B : Paclitaxel - coated balloons - Survey of preclinical data .", "label": "", "metadata": {}, "score": "142.65898"}
{"text": "IN.PACT DEEP was initiated as the first trial to systemically assess the Safety and Efficacy of the new IN.PACT Amphirion \u2122 paclitaxel drug - eluting balloon ( IA - DEB ) technology in CLI patients with infrapopliteal disease .", "label": "", "metadata": {}, "score": "144.49359"}
{"text": "PubMed .Copyright .\u00a9 Arroyo et al . ; licensee BioMed Central Ltd. 2014 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "157.08182"}
{"text": "PubMed .Copyright .\u00a9 Zeller et al . ; licensee BioMed Central Ltd. 2014 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "159.18544"}
